

CITATION REPORT

List of articles citing

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (48)

DOI: 10.1016/s0002-9149(97)00904-1

American Journal of Cardiology, 1998, 81, 333-5.

Source: <https://exaly.com/paper-pdf/28950751/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
427	Does cholesterol lowering prevent stroke?. 1998 , 23, 337-44		5
426	Lipid-lowering for lower limb atherosclerosis. 2000 , CD000123		10
425	2. Cholesterol in perspective. 1999 , 170, 385-390		1
424	Statins and cerebrovascular disease: plaque attack to prevent brain attack. 1999 , 4, 269-72		8
423	Natural statins and stroke risk. 1999 , 99, 185-8		100
422	A prospective study of egg consumption and risk of cardiovascular disease in men and women. 1999 , 281, 1387-94		314
421	Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. 1999 , 99, 216-23		357
420	Treating patients with hypertriglyceridaemia saves lives: triglyceride revisited. 1999 , 15, 65-77		12
419	[Angiology update]. 1999 , 94, 251-63		0
418	Chirurgische Gefäßmedizin der Zukunft: interdisziplinäre Strategien. 1999 , 31, 235-242		
417	Peripheral Arterial Disease. 1999 , 1, 27-34		5
416	Terje Rolf Pedersen, MD: a conversation with the editor. Interview by William Clifford Roberts. <i>American Journal of Cardiology</i> , 1999 , 84, 1234-45	3	
415	Lipids and vascular disease: what we do and do not know. 1999 , 286, 7-22		5
414	Cholesterol and stroke. 1999 , 9, 1-12		2
413	Low-density lipoprotein-independent effects of statins. 1999 , 10, 543-59		166
412	Effects of statins on carotid disease and stroke. 1999 , 10, 535-41		5
411	Preventing ischemic stroke. Current approaches to primary and secondary prevention. 2000 , 107, 34-6, 39-42, 47-50		15

410	EPIDEMIOLOGIC DATA IN CLINICAL PRACTICE. 2000 , 48, 1157-1162		32
409	Peripheral vascular disease and type 2 diabetes mellitus. 2000 , 16 Suppl 1, S11-5		33
408	Overall strategy and basic treatment for intermittent claudication. 2000 , 19, S66-S76		
407	Current and emerging therapies for lower extremity peripheral arterial disease. 2000 , 9, 37-39		3
406	The imperative to raise low levels of high-density lipoprotein in cholesterol--a better clinical strategy in the prevention and treatment of coronary artery disease. Introduction. <i>American Journal of Cardiology</i> , 2000 , 86, 1L-4L	3	1
405	How do vascular surgeons perceive atherosclerotic risk factor management?. 2000 , 14, 652-8		6
404	Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis. 2000 , 2, 321-6		4
403	Vascular surgery between the millenniums. <i>Vasa - European Journal of Vascular Medicine</i> , 2000 , 29, 17-27	1.9	2
402	HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. 2000 , 54, 790-6		101
401	Better outcome after stroke with higher serum cholesterol levels. 2000 , 54, 1944-9		136
400	Pravastatin therapy and the risk of stroke. 2000 , 343, 317-26		268
399	Treatment of intermittent claudication. 2000 , 31, S77-S89		4
398	Current perspectives on statins. 2000 , 101, 207-13		958
397	HMG-CoA reductase inhibitors and myotoxicity. 2000 , 22, 441-57		203
396	Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. 2000 , 36, 766-72		103
395	Simvastatin improves arterial compliance in the lower limb but not in the aorta. <i>Atherosclerosis</i> , 2001 , 155, 245-50	3.1	69
394	Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. <i>Atherosclerosis</i> , 2001 , 159, 201-8	3.1	77
393	Medical treatment of peripheral arterial disease and claudication. 2001 , 344, 1608-21		856

392	Clinically relevant differences between the statins: implications for therapeutic selection. 2001 , 111, 390-400		154
391	HMG-CoA reductase inhibitors. 2001 , 56, 77-114		31
390	Hipertensi3n arterial en el paciente dislipidico. 2001 , 13, 179-194		1
389	Pharmacology and clinical experience with simvastatin. 2001 , 2, 153-63		20
388	Statins in the 21st century: end of the simple story?. 2001 , 10, 1755-66		17
387	Simvastatin: building on success. 2001 , 62, 29-32		
386	Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. 2001 , 11 Suppl 1, 85-95		29
385	[Lipid therapy. Prevention of arteriosclerotic cardiovascular diseases]. 2001 , 42, 92-110		2
384	Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. <i>American Journal of Cardiology</i> , 2001 , 87, 3D-13D	3	97
383	Are we aggressive enough in lowering cholesterol?. <i>American Journal of Cardiology</i> , 2001 , 88, 10F-5F	3	10
382	Developing a clinical strategy for cholesterol management in an era of unanswered questions. <i>American Journal of Cardiology</i> , 2001 , 88, 25F-30F	3	2
381	Ongoing clinical trials of statins. <i>American Journal of Cardiology</i> , 2001 , 88, 36F-40F	3	16
380	Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease. <i>American Journal of Cardiology</i> , 2001 , 88, 43J-47J	3	42
379	Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. <i>American Journal of Cardiology</i> , 2001 , 88, 33J-37J	3	21
378	Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines. <i>American Journal of Cardiology</i> , 2001 , 88, 37K-41K	3	10
377	Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. 2001 , 56, M138-45		20
376	Statins for stroke: the second story?. 2001 , 103, 348-50		16
375	Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). 2001 , 103, 2828-33		219

374	Treatment of the elderly post-myocardial infarction patient. 2001 , 10, 316-22, 376	2
373	Pharmacologic therapy of lipid disorders in the elderly. 2002 , 11, 247-56	5
372	Peripheral arterial disease: epidemiology and drug therapy. 2002 , 11, 258-66	14
371	Should hypercholesterolemia in older persons be treated to reduce cardiovascular events?. 2002 , 57, M411-3	11
370	Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. 2002 , 106, 1595-8	9
369	The diabetic foot: pathogenesis and clinical evaluation. 2002 , 2, 221-8	15
368	Coronary artery disease and intermittent claudication: how to manage the patient. 2002 , 4, B58-B62	1
367	Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. 2002 , 87, 423-37	56
366	Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. 2002 , 287, 2570-81	1786
365	Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. 2002 , 106, 1690-5	156
364	Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. 2002 , 7, 323-31	33
363	Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. 2002 , 105, 2583-5	47
362	Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication. 2002 , 42, 1291-8	13
361	Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity. 2002 , 4, B50-B54	2
360	Peripheral arterial disease: medical care and prevention of complications. 2002 , 5, 119-30	19
359	Who should receive HMG CoA reductase inhibitors?. 2002 , 62, 1707-15	11
358	Carotid stenosis: medical and surgical aspects. 2002 , 20, 599-609	9
357	Factores de riesgo y factores pronósticos en la arteriosclerosis precoz de extremidades inferiores. 2002 , 54, 145-161	2

356	Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatment. 2002 , 20, 169-81	12
355	Various interventions have potentially major economic impact in intermittent claudication. 2002 , 18, 23-26	
354	Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. 2002 , 360, 1623-30	2597
353	Beyond lipid lowering: the role of statins in vascular protection. 2002 , 86, 5-18	205
352	Should Hypercholesterolemia Be Treated in Frail Elders?. 2002 , 3, 66-70	1
351	Tratamiento médico de la claudicación intermitente. 2002 , 54, 162-173	2
350	Pharmacologic therapy for peripheral arterial disease and claudication. 2002 , 36, 1283-91	62
349	Hipertensión arterial en el paciente dislipidémico. 2002 , 19, 222-237	
348	Management of intermittent claudication. 2002 , 20, 521-34	5
347	Bone formation in carotid plaques: a clinicopathological study. 2002 , 33, 1214-9	203
346	Management of intermittent claudication: the importance of secondary prevention. 2002 , 23, 100-7	21
345	[Statins and cerebrovascular events]. 2002 , 27, 765-71	1
344	Beyond lipid-lowering: effects of statins on endothelial nitric oxide. 2003 , 58, 719-31	137
343	Risk factor documentation in elective and emergency vascular surgical admissions. 2003 , 25, 568-72	4
342	Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. <i>American Journal of Cardiology</i> , 2003 , 92, 711-2	3 144
341	Impact of the new National Cholesterol Education Program (NCEP) guidelines on patient management. 2003 , 15, 350-60	3
340	Lipid Management: Case by Case. 2003 , 14, P29-P30	
339	Clinical implications of carotid artery remodeling in acute coronary syndrome: ultrasonographic assessment of positive remodeling. 2003 , 42, 1026-32	39

338	Pharmacological treatment of patients with peripheral arterial disease. 2003 , 63, 637-47	9
337	Vascular Surgery. 2003 ,	
336	Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. 2003 , 114, 359-64	213
335	Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. <i>Atherosclerosis</i> , 2003 , 171, 337-42	3.1 38
334	Statin therapy in the elderly: does it make good clinical and economic sense?. 2003 , 20, 263-75	15
333	Review: Lipids and stroke. 2003 , 3, 170-176	2
332	Clinical trials: Evidence and unanswered questions--hyperlipidaemia. 2003 , 16 Suppl 3, 25-32	12
331	Potential nontraditional applications of statins. 2003 , 37, 1063-71	13
330	Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. 2003 , 108, 1481-6	359
329	Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. 2003 , 107, 1848-51	383
328	Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. 2003 , 107, 757-61	179
327	Association of abnormal serum lipids in elderly persons with atherosclerotic vascular disease and dementia, atherosclerotic vascular disease without dementia, dementia without atherosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. 2003 , 58, M859-61	20
326	Cholesterol and the risk of ischemic stroke. 2003 , 34, 2930-4	108
325	The statins: multifunctional antithrombotic and antineoplastic drugs. 2003 , 29, 259-74	9
324	Oral anticoagulant therapy in patients with peripheral artery disease. 2003 , 3, 339-44	6
323	Women do benefit from lipid lowering: latest clinical trial data. 2003 , 11, 4-12	16
322	Statins as potential therapeutic agents in neuroinflammatory disorders. 2003 , 16, 393-401	86
321	Process of care and outcomes in peripheral arterial disease. 2003 , 325, 125-34	14

320	Literatur. 2003 ,		
319	Statins as potential therapeutic agents in neuroinflammatory disorders. 2003 , 16, 393-401		59
318	Statins in the Primary Prevention of Atherosclerosis-Related Events. 2004 , 53-92		
317	Secondary Prevention of Atherosclerosis and Related Events by Statins. 2004 , 93-112		
316	What does the future hold for the patient with peripheral arterial disease?. 2004 , 6, C43-C48		0
315	Lipid-lowering therapy in patients with peripheral arterial disease. 2004 , 9, 303-6		
314	Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. 2004 , 9, 185-92		22
313	Dyslipoproteinemia and peripheral arterial occlusive disease. 2004 , 55, 135-8		6
312	Statins for the prevention of cerebrovascular disease: the rationale for robust intervention. 2004 , 6, C34-C42		2
311	Lipid-lowering therapy in patients with peripheral arterial disease. 2004 , 9, 271-7		6
310	The influence of statin characteristics on their safety and tolerability. 2004 , 58, 945-55		31
309	Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. 2004 , 57, 640-51		212
308	Metabolic syndrome and risk of stroke. 2004 , 6 Suppl 3, S30-4		4
307	The role of statins in vascular disease. 2004 , 27, 6-16		44
306	Understanding physician and consumer attitudes concerning cholesterol management: results from the National Lipid Association surveys. <i>American Journal of Cardiology</i> , 2004 , 94, 9F-15F	3	53
305	Multi-bed vascular disease: past, present, and future. 2004 , 17, 5-9		
304	Lipids and the elderly. 2004 , 5, 359-64		7
303	[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease]. 2004 , 29, 12-6		0

302	New and emerging data from clinical trials of statins. 2004 , 6, 12-9	8
301	Statin as potential therapeutic agents in multiple sclerosis. 2004 , 4, 237-44	9
300	Simvastatin: a review. 2004 , 5, 2583-96	72
299	Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. 2004 , 39, 1178-85	148
298	Medical treatment of peripheral arterial disease: a comprehensive review. 2004 , 15, 1197-207	69
297	Exercise, Drugs, and Time—That's All You Need. 2004 , 15, P127-P129	
296	The role of cilostazol in the treatment of intermittent claudication. 2004 , 20, 1661-70	18
295	Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. 2004 , 116, 96-103	196
294	Effect of Simvastatin Versus Placebo on Treadmill Exercise Time Until the Onset of Intermittent Claudication in Older Patients With Peripheral Arterial Disease at Six Months and at One Year After Treatment. 2004 , 16, 334-336	
293	Management of peripheral arterial disease of the lower extremities in elderly patients. 2004 , 59, 172-7	42
292	The Top 12 Advances in Vascular Medicine. 2004 , 11, II-21-II-31	1
291	Hyperlipidemia in Peripheral Arterial Disease. 2005 , 61-73	1
290	Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic. 2005 , 13, 108-10	18
289	Management of peripheral arterial disease. 2005 , 13, 61-8	54
288	Statins and cardiovascular risks. 2005 , 43, 55-68	4
287	Peripheral Arterial Disease in the Elderly. 2005 , 301-318	
286	Medical management of peripheral arterial disease. 2005 , 3, 1628-37	43
285	Diabetes mellitus and stroke. 2006 , 60, 48-56	78

284	Simvastatin Effects in Normo- and Hypercholesterolaemic Patients with Peripheral Arterial Occlusive Disease: A Pilot Study. 2005 , 96, 413-419	10
283	Comprehensive endovascular therapy for femoropopliteal arterial atherosclerotic occlusive disease. 2005 , 201, 275-96	32
282	The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst. 2005 , 4, 3	6
281	Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. 2005 , 12, 205-10	69
280	Doen arterial obstrutiva perifica: que aten temos dispensado abordagem clica dos pacientes?. 2005 , 4, 255-264	7
279	Cardiovascular Disease in the Elderly. 2005 ,	
278	Lipids and stroke: the opportunity of lipid-lowering treatment. 2005 , 20 Suppl 2, 53-67	13
277	Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. 2005 , 12, 443-52	44
276	Managing abnormal blood lipids: a collaborative approach. 2005 , 112, 3184-209	164
275	Temporal trends in the incidence of intermittent claudication from 1950 to 1999. 2005 , 162, 430-7	38
274	Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient. 2005 , 6, 2181-92	2
273	Lower Extremity Arterial Disease. 2005 ,	1
272	Treatment with statins in the acute phase of ischemic stroke. 2005 , 5, 211-21	19
271	Preoperative statin therapy does not reduce cognitive dysfunction after cardiopulmonary bypass. 2005 , 19, 294-9	26
270	Management of peripheral arterial disease in chronic kidney disease. 2005 , 23, 225-36	34
269	Cardiovascular risk prevention in peripheral artery disease. 2005 , 41, 1070-3	18
268	Progress in the identification of stroke-related genes: emerging new possibilities to develop concepts in stroke therapy. 2005 , 19, 821-32	9
267	Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. 2005 , 99, 269-75	54

266	Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. 2005 , 45, 336-42	223
265	Atherosclerotic risk factor control in patients with peripheral arterial disease. 2005 , 41, 816-22	76
264	Managing hyperlipidaemia in the elderly: special considerations for a population at high risk. 2006 , 23, 181-9	12
263	Drug treatment of peripheral arterial disease in the elderly. 2006 , 23, 1-12	9
262	A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease. 2006 , 44, 531-6	128
261	Optimal medical management of peripheral arterial disease. 2006 , 40, 312-27	52
260	The Diabetic Foot. 2006 ,	9
259	Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. 2006 , 43, 1205-10	19
258	Peripheral arterial disease in patients with diabetes. 2006 , 47, 921-9	328
257	ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients. 2006 , 47, 51-192	184
256	Peripheral arterial disease in patients with diabetes mellitus. 2006 , 99, 707-8	
255	Vascular surgery critical care: perioperative cardiac optimization to improve survival. 2006 , 34, S200-7	18
254	The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients. 2006 , 8, 8-14	6
253	Lipid-lowering therapy in high-risk persons. 2006 , 32, 68-73	2
252	Statins and peripheral arterial disease: potential mechanisms and clinical benefits. 2006 , 20, 696-705	38
251	Statin therapy for coronary heart disease and its effect on stroke. 2006 , 8, 337-42	3
250	Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?. <i>American Journal of Cardiology</i> , 2006 , 98, 18P-25P	3 52
249	5-year evaluation of electronic medical record flag alerts for patients warranting secondary prevention of coronary heart disease. 2006 , 26, 682-8	4

248	Medical Management of Peripheral Arterial Disease: A Therapeutic Algorithm. 2006 , 13, II-19-II-29	5
247	Preventive Cardiology. 2006 ,	
246	Medical Management of Peripheral Arterial Disease: A Therapeutic Algorithm. 2006 , 13, II-19-II-29	4
245	Medical treatment of peripheral arterial disease. 2006 , 295, 547-53	231
244	ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of: 2006 , 113, e463-654	2378
243	Statins in stroke: prevention, protection and recovery. 2006 , 6, 195-202	19
242	Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. 2007 , 41, 138-41	12
241	Treatment of Diabetic Foot Ulcers. 2007 , 7, 95-104	2
240	Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. 2007 , 16, 36-44	66
239	The evaluation of cardiac and peripheral arterial disease in patients with diabetes mellitus. 2007 , 32, 109-42	3
238	Peripheral Arterial Disease. 2007 ,	
237	Author Index To Volume 3. 2007 , 4, 1-3	
236	Lipid management and peripheral arterial disease. 2007 , 8, 561-70	12
235	Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. 2007 , 45, 645-654; discussion 653-4	270
234	The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. 2007 , 45, 47-54	32
233	Noninvasive Vascular Diagnosis. 2007 ,	8
232	Pharmacological interventions for peripheral artery disease. 2007 , 8, 1465-77	9
231	Simvastatin pretreatment reduces the severity of limb ischemia in an experimental diabetes model. 2007 , 45, 590-6	15

230	Global cardiovascular risk: The benefits of a precocious, aggressive treatment strategy. 2007 , 1303, 113-120	1
229	Primary Prevention of Ischemic Heart Disease. 2007 , 178-220	1
228	Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. 2007 , 37, 157-64	10
227	Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. 2007 , 33, 442-50	54
226	The rationale for using HMG-CoA reductase inhibitors (β statins) in peripheral arterial disease. 2007 , 33, 192-201	18
225	Medical therapy for intermittent claudication. 2007 , 34, 314-21	27
224	Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events. 2007 , 38, 479-88	30
223	Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. 2007 , 113, 378-93	55
222	Pharmacotherapy before and after revascularization: anticoagulation, antiplatelet agents, and statins. <i>Seminars in Vascular Surgery</i> , 2007 , 20, 10-4	1.2 20
221	Management of peripheral arterial disease of the lower extremities. 2007 , 33, 247-56	7
220	Aggressive statin therapy for acute coronary syndromes. 2007 , 9, 298-302	
219	Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. 2007 , 31, 695-704	19
218	[Importance of the ankle-brachial index (ABI) in the prevention of cardiovascular diseases. Ten questions and answers]. 2007 , 32, 404-9	3
217	SPARCL: the glimmer of statins for stroke risk reduction. 2007 , 9, 347-51	3
216	[Angiology]. 2008 , 103, 198-209	3
215	Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994-2003. 2008 , 9, 39	6
214	Optimal risk factor modification and medical management of the patient with peripheral arterial disease. 2008 , 71, 475-89	41
213	Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. 2008 , 18, 1151-6	42

212	Lipoprotein-associated phospholipase A2 and risk of stroke. <i>American Journal of Cardiology</i> , 2008 , 101, 34F-40F	3	54
211	Combined simvastatin-manidipine protect against ischemia-reperfusion injury in isolated hearts from normocholesterolemic rats. 2008 , 587, 224-30		8
210	Management of hypertension in peripheral arterial disease. 2008 , 50, 238-63		35
209	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. 2008 , 7, 717-25		53
208	Pre-operative risk assessment and risk reduction before surgery. 2008 , 51, 1913-24		121
207	Vascular Complications in Human Disease. 2008 ,		
206	Angina pectoris is a stronger indicator of diffuse vascular atherosclerosis than intermittent claudication: Framingham study. 2008 , 61, 951-7		9
205	Peripheral arterial disease in the elderly: recognition and management. 2008 , 8, 353-64		26
204	A cerebrovascular perspective of atherosclerosis. 2009 , 92, 215-38		0
203	Buflomedil in peripheral arterial disease: trials and tribulations. 2008 , 117, 717-9		6
202	Clinical significance of carotid bruits: an innocent finding or a useful warning sign?. 2008 , 30, 523-30		16
201	Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study. 2008 , 59, 269-77		2
200	National health care costs of peripheral arterial disease in the Medicare population. 2008 , 13, 209-15		238
199	Pharmacotherapy before and after endovascular repair of abdominal aortic aneurysms. 2008 , 6, 240-9		22
198	Benefits of Exercise Training in Secondary Prevention of Coronary and Peripheral Arterial Disease. 2008 , 5, 156-168		4
197	Peripheral arterial disease in patients with diabetes mellitus. 2008 , 69, 570-4		2
196	Treatment of high-risk older persons with lipid-lowering drug therapy. 2008 , 15, 102-7		16
195	Management of peripheral arterial disease in the elderly: focus on cilostazol. 2008 , 3, 17-23		10

194	Peripheral arterial disease in the elderly. 2007 , 2, 645-54	38
193	Natural History and Medical Management of Chronic Lower Extremity Ischemia. 2009 , 119-136	
192	Secondary Stroke Prevention, and the Role of Antiplatelet Therapies. 2009 , 1, CMT.S2208	
191	Low fat diets for acquired hypercholesterolemia. 2009 ,	
190	Statins. 2009 , 253-280	5
189	Medical management of risk factors for vascular disease. 2009 , 27, 320-325	
188	Diabetes mellitus and cerebrovascular disease: which are the actual data?. 2009 , 23, 283-96	19
187	Pharmacologic therapy for intermittent claudication. 2009 , 29, 526-53	10
186	Screening bei peripherer arterieller Verschlusskrankheit. 2009 , 14, 370-375	1
185	Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. 2009 , 98, 249-56	51
184	What do the statin trials tell us?. 2001 , 24, III3-7	6
183	The patient with cardiovascular disease: Treatment strategies for preventing major events. 2009 , 29, 4-12	78
182	Treatment strategies for peripheral artery disease. 2009 , 10, 1571-86	8
181	Peripheral arterial disease in women. 2009 , 64, 204-11	16
180	The benefit of statins in non-cardiac vascular surgery patients. 2009 , 49, 260-5	34
179	[Peripheral arterial disease with lower limb claudication: Medical treatment]. 2009 , 34, 323-9	
178	[Implications of the REACH registry for vascular surgery]. 2009 , 132 Suppl 2, 25-9	1
177	Update on peripheral arterial disease and claudication rehabilitation. 2009 , 20, 627-56	5

176	Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. 2009 , 5, 296-311	54
175	Management of hypercholesterolemia in older persons for the prevention of cardiovascular disease. 2010 , 18, 132-40	16
174	The influence of socio-economic deprivation on rates of major lower limb amputation secondary to peripheral arterial disease. 2010 , 40, 76-80	37
173	[Life-habit intervention in a public institution]. 2010 , 94, 730-7	2
172	Arzneiverordnungs-Report 2010. 2010 ,	28
171	Silence of the limbs pharmacological symptomatic treatment of intermittent claudication. 2010 , 8, 383-7	5
170	Medical management of carotid stenosis. 2010 , 22, 18-27	8
169	The Management of Peripheral Arterial Disease in Patients with Type 2 Diabetes. 393-402	
168	New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery. 2010 , 51, 242-51	52
167	Uninsured South Florida vascular surgery patients are less likely to receive optimal medical management than their insured counterparts. 2010 , 51, 4S-8S	8
166	Does endothelial dysfunction contribute to the clinical status of patients with peripheral arterial disease?. 2010 , 26 Suppl A, 45A-50A	36
165	Statin prescription is essential in peripheral vascular disease. 2010 , 21, 175-7, quiz 178	1
164	[The role of statins in atherosclerotic peripheral arterial disease]. 2011 , 30, 665-73	
163	The role of statins in atherosclerotic peripheral arterial disease. 2011 , 30, 665-673	
162	Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. 2011 , 58, 1068-76	22
161	Medical management of the patient with intermittent claudication. 2011 , 29, 363-79	10
160	Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina. 2011 , 124, 681-8	14
159	Socio-medical Characteristics of Coronary Disease in Bosnia and Herzegovina and the World. 2011 , 23, 171-83	18

158	Secondary Pharmacotherapeutic Prevention among German Primary Care Patients with Peripheral Arterial Disease. 2011 , 2011, 316496	8
157	The rise of cholesterol testing: how much is unnecessary. 2011 , 61, e81-8	13
156	Comprehensive medical management of peripheral arterial disease. 2011 , 54, 2-13	20
155	The PANDORA study: peripheral arterial disease in patients with non-high cardiovascular risk. 2011 , 6, 509-19	25
154	The anti-ischemic and anti-anginal properties of statins. 2011 , 13, 43-50	22
153	Low-fat diets for acquired hypercholesterolaemia. 2011 , CD007957	4
152	Treatment of diabetic vasculopathy: an overview. 2011 , 21	0
151	Medical therapy for peripheral arterial disease. 2012 , 27, 592-7	12
150	LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?. 2012 , 7, 141-149	7
149	Sekundärprävention mit Rauchstopp, Medikamenten und Gehtraining. 2012 , 12, 36-40	
148	Antiplatelet and anticoagulation strategies in the prevention and treatment of ischemic stroke. 2012 , 18, 5261-72	5
147	Critical limb ischemia: epidemiology. 2012 , 8, 10-4	57
146	Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. 2012 , 55, 371-9; discussion 380	62
145	Preventive aspects in peripheral artery disease. 2012 , 6, 53-70	6
144	Peripheral Arterial Disease. 2012 , 517-527	
143	Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. 2012 , 60, 641-54	64
142	Use of statins in lower extremity artery disease: a review. 2012 , 12 Suppl 1, S15	13
141	Peripheral arterial disease of the lower extremities. 2012 , 8, 375-88	32

140 Lower Extremity Peripheral Arterial Disease. **2012**,

139 Medical therapy in peripheral artery disease. **2012**, 126, 491-500

60

138 The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. **2012**, 13, 1469-80

9

137 Medical management of risk factors for vascular disease. **2012**, 30, 377-382

136 Statin use and lower extremity amputation risk in nonelderly diabetic patients. **2013**, 58, 1578-1585.e1

34

135 Noninvasive Vascular Diagnosis. **2013**,

8

134 Overview of Peripheral Arterial Disease of the Lower Extremity. **2013**, 261-285

133 Medical Treatment of Peripheral Artery Disease. **2013**, 242-258

6

132 Peripheral Artery Disease. **2013**, 539-552

1

131 Challenges associated with peripheral arterial disease in women. **2014**, 10, 115-28

26

130 Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. **2014**, 46, 475-89

9

129 HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. **2014**, CD007784

66

128 Pre and Post-stroke Use of Statins Improves Stroke Outcome. **2014**, 39, 214-7

4

127 Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysis. **2014**, 20, 522-32

28

126 Optical coherence tomography images of iliac artery fibromuscular dysplasia. **2014**, 35, 2872

4

125 Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. **2014**, 35, 2864-72

176

124 The impact of peripheral arterial disease on patients with congestive heart failure. **2014**, 10, 327-38

6

123 Do the Effects of Secondary Prevention of Cardiovascular Events in PAD Patients Differ from Other Atherosclerotic Disease?. **2015**, 16, 14477-89

8

122	Lipid-lowering therapy in older persons. 2015 , 11, 43-56		14
121	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. 2015 , 101, 356-62		33
120	Medical management of risk factors for vascular disease. 2015 , 33, 302-307		
119	Impact of pharmacologic interventions on peripheral artery disease. 2015 , 57, 510-20		4
118	Comprehensive Management of High Risk Cardiovascular Patients. 2016 ,		1
117	Predictive factors for better bypass patency and limb salvage after prosthetic above-knee bypass reconstruction. 2016 , 64, 380-388.e1		20
116	Type 2 Diabetes. 2016 ,		2
115	Treatment of Hypercholesterolemia in 2015. 2017 , 24, e121-e129		2
114	2017 Taiwan lipid guidelines for high risk patients. <i>Journal of the Formosan Medical Association</i> , 2017 , 116, 217-248	3.2	87
113	Risk Factors for Mortality Among Individuals With Peripheral Arterial Disease. <i>American Journal of Cardiology</i> , 2017 , 120, 862-867	3	15
112	Medical Therapy of Peripheral Artery Disease. 2017 , 111-127		
111	Disruption of mitochondrial quality control in peripheral artery disease: New therapeutic opportunities. 2017 , 115, 96-106		11
110	Cardiovascular Disease and Diabetes: Two Sides of the Same Coin!. 2017 ,		
109	The burden and characteristics of peripheral arterial disease in patients undergoing amputation in Korle Bu Teaching Hospital, Accra, Ghana. 2017 , 51, 108-114		4
108	Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. 2018 , 23, 97-106		16
107	[Peripheral arterial disease: Treatment]. 2018 , 47, 56-61		
106	Nitric oxide donors for peripheral artery disease. 2018 , 39, 77-85		4
105	The association of statin therapy with the primary patency of femoral and popliteal artery stents. 2018 , 67, 1472-1479		3

104	HYPOLIPIDEMIC THERAPY IN STROKE PREVENTION: EXISTING STANDARDS, EVIDENCE-BASED MEDICINE DATA AND REAL PRACTICE. 2018 , 14, 434-440		3
103	[Peripheral Arterial Disease: When is a PCSK9 Inhibitor Useful?]. 2018 , 143, 1391-1396		1
102	Dyslipidemia Profiles in Patients with Peripheral Artery Disease. 2019 , 21, 42		11
101	Drug Therapy of Dyslipidemia in the Elderly. 2019 , 36, 321-340		13
100	Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. <i>Atherosclerosis</i> , 2020 , 293, 94-100	3.1	37
99	Use of statins in patients with peripheral artery disease. 2020 , 30, 257-262		1
98	Editorial commentary: Peripheral arterial disease and statin therapy, what do we know after all these years?. 2020 , 30, 263-264		
97	Forty-eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas. 2021 , 12, 1278-1286		2
96	Current and emerging drug treatment strategies for peripheral arterial disease. 2020 , 21, 1603-1616		4
95	LDL-Cholesterol versus Glucose in Microvascular and Macrovascular Disease. 2021 , 67, 167-182		2
94	Overview of Peripheral Arterial Disease of the Lower Extremity. 2021 , 1-40		
93	Maximizing the medical support, the first essential complementary treatment - controlling the infection, protecting the heart and the brain. 2021 , 27,		0
92	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. 2021 , 3, 936-949		0
91	Characteristics of atherosclerosis in femoropopliteal artery and its clinical relevance. <i>Atherosclerosis</i> , 2021 , 335, 31-40	3.1	1
90	The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?. 2021 , 23, 13		3
89	Peripheral vascular disease and Type 2 diabetes mellitus. 2000 , 16, S11-S15		3
88	Prevention of Peripheral Artery Atherosclerosis. 2002 , 1347-1350		2
87	Durchblutungsffördernde Mittel. 2001 , 390-401		1

86	Vascular Diseases of the Nervous System. 2008 , 1165-1223		4
85	Vascular Diseases of the Nervous System. 2012 , 1003-1053		3
84	ESVM Guideline on peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2019 , 48, 1-79	1.9	46
83	5 Conservative treatment for PAD - Risk factor management. <i>Vasa - European Journal of Vascular Medicine</i> , 2019 , 48, 1-12	1.9	6
82	Preventive cardiology. 1999 , 14, 382-91		3
81	Primary and secondary prevention of coronary artery disease: a follow-up on clinical controlled trials. 1998 , 9, 557-64		5
80	Medical prevention of stroke, 2003. 2003 , 96, 354-8		10
79	Evidence-Based Medical Management of Peripheral Artery Disease. 2020 , 40, 541-553		26
78	Hyperlipidemia and Diabetes Mellitus. 2002 ,		1
77	The top 12 advances in vascular medicine. 2004 , 11 Suppl 2, II21-31		1
76	Management of hyperlipidemia with statins in the older patient. 2006 , 1, 433-8		5
75	Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy?. 2005 , 1, 111-7		7
74	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. 2015 , 19, 1-401, vii-viii		23
73	Lipid-Lowering Drugs. 2000 , 155-177		
72	Durchblutungsffördernde Mittel. 2000 , 306-316		
71	Praxis der Lipid senkenden Therapie in der kardiologischen Rehabilitation. 2001 , 125-131		
70	Durchblutungsffördernde Mittel. 2001 , 354-365		
69	Periphere und zentrale Durchblutungsstörungen. 2002 , 399-407		

- 68 Indications and contra-indications for statin treatment (primary and secondary prevention of hypercholesterolemia). **2002**, 99-120
- 67 Clinical experience: studies with HMG-CoA reductase inhibitors. **2002**, 121-133
- 66 References. **2002**, 106, 3373-3421 1
- 65 Durchblutungsffdernde Mittel. **2003**, 417-429
- 64 Cardiovascular Risk Factors and Peripheral Arterial Disease. **2003**, 113-120
- 63 Lipid-Lowering Drugs. **2003**, 165-191
- 62 Arterial Occlusive Diseases of the Extremities. **2003**, 47-79
- 61 Peripheral Vascular Disease in Diabetes.
- 60 The Scandinavian Simvastatin Survival Study (4S). **2003**, 96-109
- 59 Durchblutungsffdernde Mittel. **2004**, 554-563
- 58 Durchblutungsffdernde Mittel. **2004**, 480-489
- 57 Bedside Platelet Monitoring. **2004**, 495-520
- 56 [Gene therapy for atherosclerosis]. **2005**, 62, 307-10 1
- 55 Advances in the Acute Treatment and Secondary Prevention of Stroke. **2005**, 21-33
- 54 Medical Treatment of Peripheral Arterial Disease. **2006**, 271-292
- 53 Lower Extremity Arterial Reconstruction in Patients With Diabetes Mellitus. **2006**, 473-492
- 52 Medical Management of Peripheral Arterial Disease:A Therapeutic Algorithm. **2006**, 13, II-19-II-29 2
- 51 Peripheral Arterial Disease. **2006**, 585-610

50 Peripheral Arterial Diseases. **2007**, 1681-1703

49 Peripheral Arterial Disease. **2007**, 379-388

1

48 The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. **2007**, 437-461

47 [Risk status of patients with peripheral arterial disease (PAD)]. **2007**, 148, 2469-76

o

46 Stroke. **2008**, 1081-1090

45 Durchblutungsffördernde Mittel. **2008**, 567-574

44 Management of Peripheral Arterial Disease in the Elderly. **2008**, 749-768

43 Pharmacological treatment in peripheral arterial disease. **2008**, 811-821

42 Durchblutungsffördernde Mittel. **2009**, 561-568

41 Risk Factor Modification in the Management of Critical Limb Ischemia. **2009**, 85-112

40 Atherosclerotic Risk Factors. **2010**, 435-449

39 Durchblutungsffördernde Mittel. **2010**, 589-596

38 Peripheral Arterial Disease. **2010**, 196-204.e2

37 Overview of Peripheral Arterial Disease of the Lower Extremity. **2010**, 1-14

36 Durchblutungsffördernde Mittel. **2011**, 607-614

35 Peripheral Arterial Disease Assessment and Management. **2011**, 512-525

34 Peripheral and Cerebrovascular Disease. **2012**, 1-17

33 Statins in the Reduction of Cardiovascular Events.

32 Durchblutungsffdernde Mittel. **2012**, 613-620

31 Cardiovascular Disease. **2012**, 478-549

30 Peripheral Arterial Disease. 345-365

29 Peripheral Arterial Disease. **2013**, 781-796

28 Durchblutungsffdernde Mittel. **1999**, 281-290

27 Overview of Peripheral Arterial Disease of the Lower Extremity. **2017**, 291-318

26 Peripheral artery disease in women. *The European Research Journal*, 178-186

0 1

25 Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. *Atherosclerosis*, **2021**, 338, 55-63

3.1 0

24 Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. *Vasa - European Journal of Vascular Medicine*, **2021**, 50, 401-411

1.9 4

23 Durchblutungsffdernde Mittel. 623-631

22 Arterielle Verschlusskrankheit (AVK). **2005**, 146-149

21 Lipide. **2005**, 362-377

20 Peripheral Arterial Disease. **2005**, 807-828

19 Low-Density Lipoprotein Cholesterol and Coronary Artery Disease. **2006**, 49-80

18 Overview of Peripheral Arterial Disease of the Lower Extremity. **2007**, 207-220

17 Current State of Medical Therapies for Peripheral Vascular Disease. **2008**, 139-149

16 Lipids and Peripheral Arterial Disease. **2007**, 35-40

15 Durchblutungsffdernde Mittel. **2007**, 619-628

14 Durchblutungs-fördernde Mittel. **2008**, 579-586

13 Stellenwert der frühzeitigen Diagnostik und Behandlung der Peripheren Arteriellen Verschlusskrankheit für die Prävention kardiovaskulärer Ereignisse. **2008**, 787-805

12 Cholesterol and cardiovascular disease in the elderly. Facts and gaps. **2013**, 4, 154-69

33

11 Comparison of efficacy and adverse effect profile of high dose versus standard dose atorvastatin in acute ST elevation myocardial infarction patients. *Heart Asia*, **2011**, 3, 82-6

1.9

1

10 Risk factors and pharmacological therapy in patients with vascular disease. **2022**, 11-24

9 Statins and Peripheral Arterial Disease: A Narrative Review. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 777016

5.4

0

8 Overview of Peripheral Arterial Disease of the Lower Extremity. **2022**, 449-488

7 Peripheral arterial disease. **2022**, 482-492

6 2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke.. *Journal of the Formosan Medical Association*, **2022**,

3.2

1

5 A Comprehensive Review on Antithrombotic Therapy for Peripheral Artery Disease. *Seminars in Vascular Surgery*, **2022**, 35, 124-124

1.2

1

4 Causal Association of Cardiovascular Risk Factors and Lifestyle Behaviors With Peripheral Artery Disease: A Mendelian Randomization Approach. **2022**, 11,

0

3 Role of Lipid-Lowering Therapy in Peripheral Artery Disease. **2022**, 11, 4872

0

2 Peripheral vascular remodeling during ischemia. 13,

0

1 The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study). **2023**,

0